{"id":18481,"date":"2024-04-16T09:21:00","date_gmt":"2024-04-16T09:21:00","guid":{"rendered":"http:\/\/model1.caplinpoint.net\/?p=18481"},"modified":"2024-05-25T06:25:54","modified_gmt":"2024-05-25T06:25:54","slug":"caplin-steriles-gets-usfda-approval-for-ofloxacin-ophthalmic-solution","status":"publish","type":"post","link":"http:\/\/model1.caplinpoint.net\/index.php\/2024\/04\/16\/caplin-steriles-gets-usfda-approval-for-ofloxacin-ophthalmic-solution\/","title":{"rendered":"CAPLIN STERILES GETS USFDA APPROVAL FOR OFLOXACIN OPHTHALMIC SOLUTION"},"content":{"rendered":"\n<p><strong>Chennai, April 16, 2024: <\/strong>Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution USP 0.3% (eye drops), a generic therapeutic equivalent version of (RLD), OCUFLOX Ophthalmic Solution of Allergan Inc.<\/p>\n\n\n\n<p>Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers. According to IQVIATM (IMS Health), Ofloxacin Ophthalmic Solution USP 0.3% had US sales of approximately $52 million for the 12- month period ending December 2023.<\/p>\n\n\n\n<div class=\"wp-block-file\"><a target=\"_blank\" href=\"http:\/\/model1.caplinpoint.net\/wp-content\/uploads\/2024\/04\/Press_Release_Ofloxacin_Ophthalmic_ANDA_Approval.pdf\" class=\"wp-block-file__button\" rel=\"noopener\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chennai, April 16, 2024: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution USP 0.3% (eye drops), a generic therapeutic equivalent version of&#8230; <\/p>\n","protected":false},"author":1,"featured_media":1229,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/18481"}],"collection":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/comments?post=18481"}],"version-history":[{"count":1,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/18481\/revisions"}],"predecessor-version":[{"id":18482,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/18481\/revisions\/18482"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media\/1229"}],"wp:attachment":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media?parent=18481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/categories?post=18481"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/tags?post=18481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}